Speaker: Professor Mhairi Copland
Summary: Professor Mhairi Copland presents two patient case studies on the management of CP CML using BOSULIF. Content recorded from the CPD approved webinar 'The Evolution of CML Management in 2023'.
Prof Copland presents the case study of a 55-year-old male covering the management of CML, including the use of BOSULIF following intolerance to other TKIs.
In this video, Prof Copland takes you through the case study of a 31-year-old male in relation to the management of TKI-resistant CML with BOSULIF.
Professor of Translational Haematology and Honorary Consultant in Haematology at the University of Glasgow
Mhairi Copland is Professor of Translational Haematology and Honorary Consultant in Haematology at the University of Glasgow. She graduated in Medicine from Aberdeen University in 1996 and obtained a PhD in Cancer Sciences from the University of Glasgow in 2007. She currently splits her time between the Paul O’Gorman Leukaemia Research Centre, where she is Director, and the Beatson West of Scotland Cancer Centre, Glasgow. She has clinical and research interests in chronic myeloid leukaemia and acute leukaemias and was chair of the UK NCRI CML Subgroup (2013-2019). She is now the deputy chair for the NCRI Haemato-oncology Clinical Study Group. Specific areas of research interest are leukaemia stem cells, novel, stem-cell directed therapies, treatment resistance and studies of the leukaemic microenvironment. She was Chief Investigator for the Phase 1 MATCHPOINT and Phase 2 TASTER clinical trials; co-chief investigator for LI-1, and local principal investigator for several acute leukaemia and CML trials and leads the ACT Trials Acceleration Programme at the Beatson.
Log in/register to download the CML checklist; a resource for HCPs to aid discussions with patients on disease status and wider comorbidities that could impact treatment decisions.
Across 3 bitesize videos, watch Professor Adam Mead, present a summary of current considerations in the management of CML, including baseline characteristics assessment and patient monitoring for first-line treatment, as well as considerations for second-line treatment.
CP, chronic phase; CML, chronic myelogenous leukaemia; NCRI, National Cancer Research Institute; TKI, tyrosine kinase inhibitor
PP-PFE-GBR-2809. March 2021
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021